ArticleScientific reports2025
Clinical diagnostic value of serum Trim24 in patients with atherosclerosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Trim24 has been implicated in inflammatory processes and lipid metabolism, yet its role in atherosclerosis (AS) remains insufficiently explored. This study aimed to evaluate the diagnostic value of serum Trim24 in AS and its association with disease severity. This prospective case-control study included 137 AS patients and 137 healthy controls. Serum Trim24 and sCD163 levels were measured using ELISA. Clinical characteristics, including lipid profiles, inflammatory markers, and the Gensini score, were collected. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for AS, severe AS, and severe stenosis. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic performance of Trim24. Serum Trim24 levels were significantly higher in AS patients compared to healthy controls. Within the AS group, Trim24 levels were higher in patients with severe AS and severe stenosis compared to their non-severe counterparts. Trim24 exhibited strong diagnostic performance for AS (AUC = 0.928), severe AS (AUC = 0.826), and severe stenosis (AUC = 0.928). Additionally, sCD163 levels were significantly lower in AS patients, especially in those with high Trim24 expression, severe AS, and severe stenosis. ROC analysis showed moderate diagnostic value of sCD163 for AS and its severity (AUC = 0.708-0.778). Curve Estimation revealed a negative correlation between Trim24 and sCD163. Multivariate logistic regression identified Trim24 was an independent risk factors for AS, severe AS, and severe stenosis, respectively. Elevated serum Trim24 levels are associated with increased AS risk and severity, likely through modulation of macrophage polarization. Trim24 demonstrates strong potential as a diagnostic biomarker for AS and its progression, supporting further investigation in larger, more diverse populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.